Compare BIO-TECHNE Corp (TECH) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs State Street PDR S&P Retail ETF — how do they compare? BIO-TECHNE Corp trades at $72.07 (market cap $11.24B), while State Street PDR S&P Retail ETF trades at $89.86. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while State Street PDR S&P Retail ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, State Street PDR S&P Retail ETF nearer its low. Which is the better fit depends on your goals.
| TECH | XRT | |
|---|---|---|
Market Cap | $11.24B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $72.29 | $92.35 |
52-Week Low | $43.31 | $77.28 |
Enterprise Value | $11.32B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
XRT trades at $90.82, up 1.08% with a bullish technical signal supported by moving averages. The ETF shows neutral oscillators like RSI at 57.83, while ADX indicates a strong trend. Support lies at $90 and resistance at $91. Recent retail sales growth and positive economic data provide a favorable backdrop, though sentiment is mixed amid inflation concerns.
Outlook is cautiously optimistic with retail sector momentum, but risks include consumer sentiment pressures and valuation headwinds. The ETF's diversification offers stability, yet macroeconomic shifts could impact performance. Investors should weigh technical strength against fundamental uncertainties in the retail space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
